Although further research is warranted, the evidence obtained so far improves our understanding on the underlying molecular mechanism and indicates that FPR3 and CCR2 might be novel therapeutic targets for ARDS treatment. This evidence concerns the gene CCR2 and acute respiratory distress syndrome.